Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
Subscribe To Our Newsletter & Stay Updated